ProCE Banner Activity

CE / CME

Targeted and Immunotherapies in Advanced Gastric Cancer: Key Data on Treatment Selection and AE Management

PCE On Demand Live Presentation

Most gastric cancer is diagnosed at an advanced stage. In the past 5 years, novel treatments, including combination immunotherapy and targeted therapies, have demonstrated encouraging responses that may help address poor prognosis for these patients. However, with this progress comes the need for education on optimal treatment selection, sequencing, and treatment-related adverse event (TRAE) management to optimize patient outcomes. This activity provides expert advice on contemporary treatment for advanced gastric cancer, with a focus on supporting data and adverse event recognition and management with novel regimens.

Physician Assistants: maximum of 1.00 hours of AAPA Category 1 CME credits Registered Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacology credit

Released: August 15, 2022

Expiration: August 14, 2023

No longer available for credit.

Share

Faculty

Sidharth Anand

Sidharth Anand, MD

Assistant Professor of Medicine                                                                                                                            Division of Hematology - Oncology                                                                                                                              UCLA David Geffen School of Medicine                                                                                                                          Los Angeles, California

Beth Sandy

Beth Sandy, MSN, CRNP

Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Acknowledgement

This activity is supported by educational grants from: AstraZeneca; Daiichi Sankyo, Inc; Merck Sharp & Dohme Corp.

Provided by

ProCE Banner

Supporters

AstraZeneca

Daiichi Sankyo, Inc.

Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Summarize guideline recommendations for biomarker testing in gastric cancer

  • Formulate strategies for the use of novel therapies in advanced gastric cancer

  • Use recommended approaches to identify and manage TRAEs in gastric cancer

Disclosure

All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Sidharth Anand, MD: consultant/advisor/speaker: Curio Science, Signatera.

James M. Cleary, MD, PhD: researcher: Apexigen, Arcus Biosciences, AstraZeneca, Bayer, Esperas Pharma, Merck, Tesaro; consultant/advisor/speaker: Blueprint Medicines, Syros Pharmaceuticals.

Beth Sandy, MSN, CRNP: consultant/advisor/speaker: Amgen, AstraZeneca, Janssen, Jazz, Merck, Takeda.

None of the members of the Planning Committee or PCE staff have any relevant financial relationships to disclose, except Beth Sandy, MSN, CRNP, and James M. Cleary, MD, PhD as noted above.

Instructions for Credit

Participants wishing to earn CE/CME credit must:

  1. View the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete evaluation form

The estimated time to complete this activity is 1.00 hour.

Release date: August 15, 2022
Expiration date: August 14, 2023

Format

On-demand webcast

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Accreditation

PCE

Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

NP course advisor: Beth Sandy, MSN, CRNP, Abramson Cancer Center, Philadelphia, Pennsylvania

Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until August 14, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA course advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

Additional Information

Program Medium

This program has been made available online.